Integrated Drug Discovery at Jubilant Biosys: Helping Biotechs achieve differentiated outcome with our 4D approach

owner image
Owner:
Cambridge Healthtech Institute
Wednesday, January 22, 2020 | 11am EST (US and Canada) / January 23, 12am CST (China) / 4pm GMT (UK) 60 min | English
Keywords:

Webinar Details

Drug discovery is a complex process that requires cross functional scientific expertise and knowledge in disease biology.  One has to cautiously and continuously apply this knowledge in the drug hunting process to be successful in drug discovery in a timely manner.

Jubilant Biosys has invested in Science and Technology and we have built an Integrated Drug Discovery site with cross functional expertise in discovery informatics, computational chemistry, medicinal chemistry, protein sciences, structural biology, assay biology, disease biology & pharmacology, DMPK & toxicology. Our specialization is small molecule drug discovery and we have technology platforms to prosecute proteins, DNA, and RNA as drug targets.

We engage with our customers from early stage target ideation, all the way through IND enabling studies to deliver a candidate. The Webinar will focus on the Integrated Drug Discovery capabilities of Jubilant Biosys and specifically, we will talk about our experience on working with Biotech and Pharma partners on Target to Candidate drug discovery programs.

More Information

Webinar Type: Upcoming

Speakers

Saravanakumar Dhakshinamoorthy, PhD Vice President, Discovery Biology, Jubiant Biosys Limited
Saravanakumar Dhakshinamoorthy, PhD Vice President, Discovery Biology, Jubiant Biosys Limited
Saravanakumar (SK) has 20 years of experience in discovery biology & pharmacology. SK has worked at leading drug discovery organizations and has held positions of increasing responsibility. SK has managed drug discovery collaborations with big pharma and biotech companies across United States, Europe & Asia that has led to candidate compounds for clinical development.

Related Webinars